Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
出版年份 2022 全文链接
标题
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
作者
关键词
-
出版物
Cancers
Volume 14, Issue 6, Pages 1526
出版商
MDPI AG
发表日期
2022-03-17
DOI
10.3390/cancers14061526
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
- (2021) Michael Dudek et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
- (2021) Masatoshi Kudo et al. Liver Cancer
- Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
- (2021) Yawen Dong et al. Cancers
- Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
- (2021) Song Chen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
- (2021) Philipp K. Haber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors in melanoma
- (2021) Matteo S Carlino et al. LANCET
- Hepatocellular Carcinoma — Origins and Outcomes
- (2021) Robin K. Kelley et al. NEW ENGLAND JOURNAL OF MEDICINE
- NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
- (2021) Anna Michelotti et al. Cells
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Immunotherapies for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Gut microbiome in HCC – Mechanisms, diagnosis and therapy
- (2020) Robert F. Schwabe et al. JOURNAL OF HEPATOLOGY
- Checkpoint inhibitor immunotherapy in kidney cancer
- (2020) Wenxin Xu et al. Nature Reviews Urology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
- (2020) Keisuke Onoi et al. Journal of Clinical Medicine
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure
- (2020) Nadine Schulte et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma
- (2020) Ching Ngar Wong et al. LIVER INTERNATIONAL
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
- (2020) Ravindra Pramod Deshpande et al. Cancers
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
- (2019) Mohsen Malehmir et al. NATURE MEDICINE
- From NASH to HCC: current concepts and future challenges
- (2019) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- 750PA phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL
- (2019) D J Pinato et al. ANNALS OF ONCOLOGY
- Anti-drug Antibodies Against Immune Checkpoint Blockers: Impairment of drug efficacy or indication of immune activation?
- (2019) Diego Enrico et al. CLINICAL CANCER RESEARCH
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Liver immunology and its role in inflammation and homeostasis
- (2016) Mark W Robinson et al. Cellular & Molecular Immunology
- Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma
- (2016) F. Aya et al. Clinical & Translational Oncology
- Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
- (2016) Sahil Mittal et al. Clinical Gastroenterology and Hepatology
- Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
- (2016) Fabio Piscaglia et al. HEPATOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The concept of immune surveillance against tumors: The first theories
- (2016) Domenico Ribatti Oncotarget
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes
- (2014) Monika Julia Wolf et al. CANCER CELL
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
- (2013) Jessica Dyson et al. JOURNAL OF HEPATOLOGY
- Immune surveillance by the liver
- (2013) Craig N Jenne et al. NATURE IMMUNOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Regulatory T Cells and Immune Tolerance
- (2008) Shimon Sakaguchi et al. CELL
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started